Business
Holding(s) in Company
Rathbones Investment Management Ltd, ultimately controlled by Rathbones Group Plc, now holds 9,679,837 ordinary shares in Fusion Antibodies plc, representing approximately 7.74 per cent. of the Company's issued share capital. These shares are registered in the name of Rathbones Nominees Limited. Disclaimer*
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\n4 February 2026\n \nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nHolding(s) in Company\n \nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, was informed today that Rathbones Investment Management Ltd (ultimately controlled by Rathbones Group Plc) now holds 9,679,837 ordinary shares of 4 pence each in the Company, representing approximately 7.74 per cent. of the Company's issued share capital. These shares are registered in the name of Rathbones Nominees Limited.\n \nEnquiries: \n \n\n\n\n\nFusion Antibodies plc\n\n\n www.fusionantibodies.com\n\n\n\n\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n\n\n\n\n\nFusion Antibodies interactive investor hub\n\n\nhttps://investorhub.fusionantibodies.com/\n\n\n\n\n \n\n\n\n\n\n\n\nAllenby Capital Limited\n\n\nTel: +44 (0) 20 3328 5656 \n\n\n\n\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nShard Capital Partners LLP\n\n\n\n\n\n\n\nDamon Heath (Joint Broker)\n\n\nTel: +44 (0) 207 186 9952\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nWalbrook PR\n\n\n Tel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nAnna Dunphy\n\n\n Mob: +44 (0)7876 741 001\n\n\n\n\n\n\n\n\n\n \nAbout Fusion Antibodies plc\nFusion Antibodies plc is a Contract Research Organisation (CRO) located in Northern Ireland that offers a integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development.\n \nThe range of services offered includes antibody discovery/generation, development, characterisation, optimisation, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antib...